Summary
Female infertility in India is rising silently, and one of its least-discussed root causes lies deep within the cell: mitochondrial dysfunction and declining NAD+ levels. India’s Surish Pharmaceuticals has launched MITOV, the country’s first clinically formulated mitochondrial optimiser.
Introduction
Every year, millions of Indian women silently carry the weight of unexplained infertility, visiting clinics, undergoing tests, and trying treatment after treatment, only to hear the frustrating phrase: “Everything looks normal.” But increasingly, reproductive medicine is pointing to a cause that standard diagnostics miss entirely: mitochondrial dysfunction at the cellular level.
The mitochondria, the energy-producing engines inside every cell, play a decisive role in female reproductive health. Oocytes (eggs) are among the most mitochondria-rich cells in the human body, and their quality is almost entirely dependent on mitochondrial energy output.
When that energy falters, egg quality deteriorates, fertilisation rates drop, and implantation becomes unreliable. This is not a hormonal story alone. At its core, it is a cellular energy story.
Surishi Pharmaceuticals, a pioneering women’s healthcare company based in New Delhi, has recognised this gap and has responded with a formulation that is the first of its kind in India.
MITOV is India’s first dedicated mitochondrial optimiser for female infertility support, a multi-ingredient, evidence-based nutraceutical that replenishes the cellular energy reserves on which women’s reproductive systems depend.
The Silent Link Between Mitochondrial Dysfunction and Female Infertility
To understand the significance of MITOV, one must first sort out the cellular changes that occur as mitochondrial health declines. All living cells contain the coenzyme NAD+ (nicotinamide adenine dinucleotide), which converts nutrients into usable energy, repairs damaged DNA, and regulates proteins that control cellular health and inflammation.
Research shows that NAD+ levels in women can decline by as much as 50% between the ages of 35 and 60, a decline that accelerates significantly with the hormonal demands of menstruation, stress, PCOS, and perimenopause.
For the oocyte, the female gamete, this decline is catastrophic. Each oocyte requires a large amount of mitochondrial energy to mature properly, undergo fertilisation, and support early embryo development.
When NAD+ levels fall and mitochondria become dysfunctional, oocytes lose their developmental competence. The result is poor egg quality, failed fertilisation, early pregnancy loss, and unexplained infertility, all of which affect hundreds of thousands of Indian women who are told their “bloodwork is fine.”
This situation is the biological reality that MITOV is formulated to address. By restoring NAD+ levels through NMN (Beta-Nicotinamide Mononucleotide), its most direct precursor, MITOV works at the foundation of female reproductive health, not at the surface.
What Makes MITOV India’s First Mitochondrial Optimizer?
MITOV is not a standard prenatal supplement. The precision mitochondrial support system developed in this study is designed for women with infertility, poor ovarian response, PCOS-related reproductive disorders, and age-related decline in oocyte quality. Its components are screened for clinical relevance, and the system can restore mitochondrial function and maintain germ cell health.
1. NMN (Beta-Nicotinamide Mononucleotide)
As the core ingredient of the MITOV formulation, NMN is the most efficient precursor for the human body to synthesize NAD⁺. It can replenish NAD⁺ reserves depleted by ageing and stress, repair ovarian function, improve oocyte quality, and extend reproductive lifespan.
2. CoQ10 (Coenzyme Q10)
Coenzyme Q10 is the most extensively researched fertility-related nutrient in reproductive medicine. As an electron carrier in the mitochondrial electron transport chain, it supports ATP production that is required for oocyte maturation and fertilisation.
Coenzyme Q10 supplementation improves the clinical pregnancy rate, the number of retrieved oocytes, and the high-quality embryo rate in women undergoing IVF. This compound has now been incorporated into the MITOV formula as a natural partner for NMN.
3. Trans-Resveratrol and Trans-Pterostilbene:
Polyphenols that amplify the NAD+ pathway can activate SIRT1 to fulfil physiological functions such as DNA repair. Trans-pterostilbene has better bioavailability than resveratrol and can deliver its functional effects to cells.
4. EGCG (Epigallocatechin Gallate)
Active ingredients extracted from green tea can reduce oxidative damage, protect mitochondria, and delay the progression of premature ageing in the female reproductive system.
Who Is MITOV For?
MITOV is specifically designed for women experiencing a range of reproductive health issues and is tailored to address mitochondrial dysfunction:
Women with unexplained infertility, who have normal fertility indicators confirmed by routine examinations yet remain unable to conceive, can adopt the MITOV cellular energy repair programme to directly target the root causes of infertility that conventional diagnostic approaches cannot detect.
Women diagnosed with PCOS and PCOD face the dual burden of mitochondrial dysfunction and insulin resistance, caused by reduced levels of NAD+ in their bodies. The intervention product MITOV boosts NAD+ levels through NMN and activates sirtuins, resolving both the condition’s cellular root causes and its hormone-related symptoms.
For women planning to receive assisted reproductive treatment who have diminished ovarian reserve and poor ovarian response, published studies have confirmed that MITOV’s combined CoQ10+NMN formulation can increase oocyte yield and improve embryo quality.
Women over the age of 35 who struggle with age-related fertility decline have unique physiological problems: accelerated NAD+ depletion and deteriorating mitochondrial function. The MITOV formulation is precisely tailored to address these conditions, with a core focus on supporting reproductive longevity rather than merely masking symptoms.
The Surishi Difference: Science Backed by the Academic Council
Every MITOV formulation is developed and validated under the guidance of the Surishi Academic Council, Surishi Pharmaceuticals’ institutional framework that ensures all products remain aligned with the latest global developments in mitochondrial medicine, reproductive science, and women’s cellular health research.
This science-first commitment means MITOV is not a commercially convenient supplement. It is an evidence-based clinical formulation designed to meet the specific biological needs of Indian women.
Surishi Pharmaceuticals also complies with WHO and GMP standards, uses premium raw materials, and follows international packaging standards, ensuring that the quality of MITOV reflects the seriousness of the health challenge it addresses.
Conclusion
Female infertility is not always a hormonal problem, and it cannot always be solved at the hormonal level alone. At its cellular root, it is often a story of declining mitochondrial energy, falling NAD+ levels, and oocytes that no longer have the biological reserves to support healthy conception.
MITOV’s first-of-its-kind mitochondrial optimiser gives women’s reproductive cells everything they need to function, mature, and thrive.
By combining NMN, CoQ10, Astaxanthin, Trans-Resveratrol, Trans-Pterostilbene, and EGCG in a single, science-backed formulation, MITOV offers Indian women a path to fertility support that begins where it should, at the foundation of life itself.
MITOV serves women struggling with infertility, PCOS, poor ovarian response, and age-related reproductive decline. As a leading solution for MITOV tablets in India, it goes beyond being a mere supplement, driving a shift in India’s reproductive healthcare from symptom management to cellular repair.
Surishi Pharmaceuticals’ commitment to making longevity science accessible and affordable for every Indian woman means that the most advanced reproductive cellular health support is no longer out of reach. It is available, evidence-based, and here.
FAQs
1. What is MITOV, and how is it different from regular fertility supplements?
MITOV is India’s first mitochondrial optimiser, specifically developed to support care for female infertility. The MITOV fertility supplement uses clinically validated NMN. CoQ10 and astaxanthin are its core components. Unlike common vitamin- and mineral-based supplements, it specifically targets mitochondrial dysfunction and NAD⁺ depletion.
2. Can MITOV help women with PCOS who are trying to conceive?
It is clinically recognised that polycystic ovary syndrome (PCOS) is closely linked to mitochondrial dysfunction and insulin resistance and that the root cause of both conditions is a decline in NAD⁺ levels. MITOV’s NMN formulation can replenish NAD+ to activate sirtuins, mitigating the negative effects of PCOS on reproductive function.
3. Is MITOV suitable for women undergoing IVF or other assisted reproductive treatments?
MITOV is only suitable for women who have poor ovarian response, diminished ovarian reserve, and are preparing to receive IVF treatment. Third-party studies show that the combined use of CoQ10 and NMN can improve reproductive-related indicators. All users must consult a reproductive specialist before using this product.
4. At what age should women consider starting MITOV?
The reproductive health product MITOV is indicated for women over 30 years old who are planning pregnancy, experience fertility difficulties, have PCOS, or have diminished ovarian reserve. After age 35, the human body’s NAD+ level drops significantly; accessing early cellular support may lead to better reproductive outcomes. A gynaecologist or reproductive specialist must be consulted before using this product.
(Message in Public Interest by Surishi Academic Council | Makers of MITOV)
